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Abstract
Background: Lymphotropism in oral squamous cell carcinoma (OSCC) is one of the most important prognostic factors 
of 5-year survival. In an effort to identify genes that may be responsible for the initiation of OSCC lymphotropism, we 
examined DNA copy number gains and losses and corresponding gene expression changes from tumor cells in 
metastatic lymph nodes of patients with OSCC.
Results: We performed integrative analysis of DNA copy number alterations (CNA) and corresponding mRNA 
expression from OSCC cells isolated from metastatic lymph nodes of 20 patients using Affymetrix 250 K Nsp I SNP and 
U133 Plus 2.0 arrays, respectively. Overall, genome CNA accounted for expression changes in 31% of the transcripts 
studied. Genome region 11q13.2-11q13.3 shows the highest correlation between DNA CNA and expression. With a 
false discovery rate < 1%, 530 transcripts (461 genes) demonstrated a correlation between CNA and expression. 
Among these, we found two subsets that were significantly associated with OSCC (n = 122) when compared to 
controls, and with survival (n = 27), as tested using an independent dataset with genome-wide expression profiles for 
148 primary OSCC and 45 normal oral mucosa. We fit Cox models to calculate a principal component analysis-derived 
risk-score for these two gene sets ('122-' or '27-transcript PC'). The models combining the 122- or 27-transcript PC with 
stage outperformed the model using stage alone in terms of the Area Under the Curve (AUC = 0.82 or 0.86 vs. 0.72, 
with p = 0.044 or 0.011, respectively).
Conclusions: Genes exhibiting CNA-correlated expression may have biological impact on carcinogenesis and cancer 
progression in OSCC. Determination of copy number-associated transcripts associated with clinical outcomes in tumor 
cells with an aggressive phenotype (i.e., cells metastasized to the lymph nodes) can help prioritize candidate transcripts 
from high-throughput data for further studies.
Background
Oral squamous cell carcinoma (OSCC) is the sixth most
common cancer worldwide. The presence of lymph node
metastasis is associated with a 50% decrease in 5-yr sur-
vival, and is the single most important prognostic factor
identified to date [1-4]. However, the mechanisms by
which OSCC cells spread from the primary site to local
lymph nodes is not well understood. Transcriptome pro-
filing has been used to gain insights into this process [1,5-
7], but the function of many of the proposed differentially
expressed transcripts is unknown. To improve the likeli-
hood of finding genes driving the carcinogenic process,
several groups have exploited the common feature of
genomic instability in cancer [8] and identified genes the
expression of which is correlated with corresponding
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DNA copy number in tumors such as brain, breast, ovar-
ian, liver, multiple myeloma, and melanoma [9-18].
In an attempt to identify novel driver genes responsible
for the OSCC metastasis, we utilized a recently devel-
oped protocol by our group for high-throughput profiling
of DNA and RNA from the same cell population obtained
by laser capture microdissection (LCM) to determine the
association between DNA copy number aberration
(CNA) and gene expression in tumor cells isolated from
metastatic lymph nodes. We reasoned that these cells
would contain those changes in the genome and tran-
scriptome that are essential to the lymphotropism of
OSCC. In addition, we tested the hypothesis that since
nodal metastases are associated with poor prognosis, the
expression of copy number-associated genes from meta-
static OSCC tumor cells is associated with survival.
Results
Study population
Selected characteristics of the 20 OSCC patients with
lymph node metastases are shown in Additional file 1,
Table S1. Eight patients had cancers arising in the
oropharynx whereas the remainder of the tumors arose
from the oral cavity. The age range was 23-84 (mean 56.8)
years. With the exception of three patients with only one
positive lymph node, the majority of patients had ≥ N2
nodal staging (i.e. multiple metastatic nodes detected).
DNA copy number aberrations in OSCC nodal metastasis
CNA events were detected in all of the 20 OSCC lymph
node metastases and in all chromosomal arms that were
covered with SNP probes (13p, 14p, 15p, 21p and 22p
were not covered by the Affymetrix 250 K Nsp SNP
array). The percentage of each genome showing CNA
ranged between 25.6% - 73.9% (mean ± sd: 48.7 ± 13.6%.
CNA was defined as the ratio of DNA copy number in
cancer cells vs. normal cells either < 0.93 or > 1.07. In par-
ticular, large regions of amplification were detected on
chromosome arms 3q, 5p, 8q, and 9q and large regions of
deletion were detected on chromosome arms 3p, 5q, 8p,
and 13q. Most of the previously reported CNA that have
previously been associated with poor outcome in patients
with OSCC or head and neck squamous cell carcinoma
[19] were detected in the samples, such as amplification
in regions 3q21-29, 5p15, 7p12, 8q21-24, 11q13, 12q24,
14q23-32, 16q22 and 20q, and deletion in regions 1p21,
5q11-12, 5q14-15, 5q31, 8p21-22, 9p21, 10p12, 11q23-25,
12q22, 18q11.2, 21q and 22q (see Additional file 2, Figure
S1).
Inferring genome DNA copy number for each transcript
Out of the 54,675 transcripts measured by the Affymetrix
U133 Plus 2.0 array, 23,484 transcripts (43.0%) remained
after filtering as described in the Methods. However, the
majority of these transcripts did not overlap with a SNP
that could be used for inferring the DNA copy number
(Additional file 3, Table S2). Therefore, we incorporated
the SNPs within a 250 kb upstream and downstream of
neighboring region for each transcript. For 18 transcripts
there were no SNPs within the 250 kb neighboring
region, leaving 23,466 transcripts for determining the
relationship between DNA copy number and gene
expression. Out of these, the DNA copy number was
inferred from at least 5 SNPs for 23,319 transcripts
(99.4% of the 23,466 transcripts) and from 1-4 SNPs, for
147 transcripts (Additional file 3, Table S2).
Association of DNA copy number on gene expression
Based on the distribution of the cancer-normal DNA
copy number ratio, the 23,466 transcripts were divided
into six subgroups, representing high level deletion (ratio
< 0.5), low level deletion (ratio: 0.5-0.93), no change
(ratio: 0.93-1.07), low- (ratio: 1.07-2), medium- (ratio: 2-
4), and high-level amplification (ratio > 4), respectively.
The average gene expression in the low level genome
amplification and deletion subgroups differed little from
that in the no change subgroup (Figure 1A). However, the
average gene expression in the high level deletion sub-
group was -0.8 (base-2 log-transformed, which is equiva-
lent to 1.7-fold lower) and the average gene expression in
the medium and high level amplification subgroups was
0.7 and 1.6 (equivalent to 1.6-fold and 3.0-fold higher),
respectively, as compared to that in the no change sub-
group (Figure 1A). Thus, there was a dose-response rela-
tionship between DNA copy number and gene expression
(Figure 1A).
To determine the relationship between DNA copy
number and individual gene expression, we applied a
robust linear regression model. The distribution of the
correlation coefficients forms a normal-shaped curve
with the mean of the distribution shifted to the positive
direction (Figure 1B), indicating a large set of the genes
having positive correlations between DNA copy number
and gene expression. Based on the p-value distribution,
we estimated that 30.6% of the transcripts showed statis-
tically significant correlations between DNA copy num-
ber and expression (Figure 1C). With a False Discovery
Rate (FDR) < 1%, we identified 530 transcripts (461
genes) with a significantly correlated DNA copy number
and expression.
Genome region 11q13.2-q13.3 shows the highest 
correlation between DNA CNA and expression in metastatic 
OSCC
Although we observed significant associations between
gene expression and CNA on all chromosomal arms cov-
ered with SNP probes (Figure 2A), chromosomal region
11q13.2-q13.3 contained a cluster of genes with signifi-Xu et al. Molecular Cancer 2010, 9:143
http://www.molecular-cancer.com/content/9/1/143
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cantly high correlation between DNA copy number and
gene expression (i.e. p < 4.26 × 10-7, Bonferroni correc-
tion value) (Figure 2B). We further examined the genes in
the region as previous studies had associated DNA ampli-
f i c a t i o n  i n  t h i s  r e g i o n  w i t h  p o o r  p r o g n o s i s  i n  O S C C
patients [20]. There were 20 probe sets in this region that
measured the expression of 12 genes (Figure 3A). Seven
of these genes, CPT1A, MRPL21, TPCN2, ORAOV1,
FADD, and PPFIA1, and an unknown transcript mea-
sured by the probe set 236113_at, showed high correla-
tion between DNA copy number and gene expression.
The remaining five genes in the same region, IGHMBP2,
MRGPRF, MYEOV, CCND1, and ANO1, showed no sig-
nificant correlation between DNA copy number and gene
expression (Figure 3B).
Copy number-associated transcripts can distinguish OSCC 
from normal oral mucosa and are associated with survival
To prioritize the 530 transcripts whose CNA and expres-
sion are significantly correlated, we examined their rela-
tionship with OSCC (vs. normal oral mucosa from
control individuals) and with survival. We used a previ-
ously reported dataset containing transcriptome profiles
for 167 OSCC primary tumors and 45 controls [21]. The
baseline characteristics of the OSCC patients included in
the survival analysis were presented previously in Ménd-
ez et al (Additional file 1, Table S1) [22]. Nineteen of the
20 patients who contributed lymph nodes for this study
were also part of the 167 patients in the testing dataset.
They were therefore excluded from further analysis.
From the remaining 148 cases, 132 had at least 4 months
of follow-up, a cut-off used to reduce the inclusion of
deaths from patients due to co-morbidities rather than
tumor biology. The range of follow-up time for these
patients known to be alive from initial enrollment
(December 16, 2003) to the date of last follow-up (April
17, 2007) was 4.4 to 38.7 months, with a median of 17.0
months. Thirty six patients had died by the end of the fol-
low-up period; there were 25 OSCC-specific deaths, nine
non-OSCC-specific deaths and two deaths of unknown
causes. To test the hypothesis that these 530 transcripts
were associated with survival, we estimated hazard ratios
(HR) for OSCC-specific mortality, adjusting for age and
sex. Although the expression profiles in this dataset were
generated using primary tumors and the DNA copy num-
ber-associated transcripts identified in this study was
based on lymph node metastases, we hypothesized some
of the changes have already happened in the primary
tumors. The selected 530 transcripts were significantly
enriched with genes differentially expressed in OSCC
cases versus controls (p < 0.001) when compared with
random gene sets of the same size. The list was also sig-
nificantly enriched with genes associated with survival (p
< 0.001). With the same cut-off value of Z-score > 6 as in
our previous study [21], 122 transcripts representing 116
genes were identified as differentially expressed in OSCC
cases versus controls (Additional file 4, Table S3). Ingenu-
ity Pathways Analysis (IPA v8.5, Ingenuity® Systems, http:/
/www.ingenuity.com was able to functionally categorize
88 of the 116 genes, of which the following molecular and
cellular functional categories with the largest number of
genes involved: "Gene Expression" (25 genes: ACTL6A,
ATF7, BAG1, CCND2, EIF2S1, EN1, ERCC5, FADD,
GTF2E1, HLTF, MBD2, MCM7, MUC1, MYNN, NFX1,
OSMR, PAK2, PBX1, RAF1, RBBP8, SLU7, SNAPC3,
TAF6, VAV3, and ZHX1), "Cell Cycle" (15 genes:
Figure 1 Influence of DNA copy number on gene expression in the 20 lymph node metastatic OSCC. A. Summary of gene expression in sub-
group of transcripts with different cancer-normal DNA copy number ratio (Box plot in each subgroup indicates 25th, 50th, and 75th percentile of the 
gene expression). X-axis: subgroups with different DNA copy number ratio. Y-axis: base-2 log-transformed relative gene expression; B. Distribution of 
the estimated correlation coefficients between DNA copy number and gene expression. X-axis: value of the correlation coefficient; Y-axis: frequency; 
C. P-value distribution for the correlation coefficients.Xu et al. Molecular Cancer 2010, 9:143
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ACTL6A, CCND2, CSNK2A2, FADD, MCM7,
MPHOSPH6, PAK2, PCM1, PPP2R2A, RAF1, RBBP8,
SENP5 (includes EG:205564), SSSCA1, TAF6, and VAV3),
and "Cell Death" (12 genes: ATF7, BAG1, CCND2,
CSNK2A2, EN1, FADD, MUC1, PAK2, PBX1, PPP2R2A,
RAF1, and TAF6). In addition, 27 transcripts represent-
ing 24 genes were associated with survival (Table 1). IPA
was able to functionally categorize 19 of the 24 genes, of
which the following molecular and cellular functional
categories with the largest number of genes involved:
"Cell Death" (CCT6A, FADD, NFE2L2, RAD23B,
STEAP3, and TREM1) and "Cellular Movement" (FADD,
NFE2L2, and PPFIA1).
Given results from our previous study showing that
genes that are differentially expressed between OSCC
and normal oral mucosa are associated with OSCC prog-
nosis [22], we tested whether gene expression levels of the
122 transcripts were associated with survival. We used
the first two principal component (PC) scores of the 122
transcripts as a predictor to fit Cox models. We also
Figure 2 Summary of genome-wide DNA copy number aberrations and concordant gene expression changes. A. Top panel: Percentage of 
genome DNA amplification (red) and deletion (green) of the 20 OSCC on the human autosomes. Only CNAs with tumor-normal DNA copy number 
ratio less than 0.7 or greater than 1.4 are counted as deleted or amplified, respectively. Bottom-panel: Manhattan plot of the negative base-10 log-
transformed p-value for the correlation coefficients between DNA copy number and gene expression for all the studied genes at each loci. Line indi-
cates the Bonferroni p-value cutoff = -log10(0.01/23,466) = 6.37; B. A close-up view of the 11q13.2-q13.3 high correlation region.Xu et al. Molecular Cancer 2010, 9:143
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tested a model using the first two PC scores of the 27 sur-
vival-associated transcripts. These two models were
compared with AJCC stage alone, a current clinical
guideline for survival prediction. The hazard ratios for
five models with either stage or PC scores or with a com-
bination of stage and PC scores are summarized in Table
2. Results from the ROC analysis for these five models are
shown in Figure 4. The AUC for a model combining stage
and the 122- or 27-transcript PC risk scores was signifi-
cantly higher than for a model with stage alone (p = 0.044
and 0.011, respectively) (Figure 4A and 4B).
Discussion
In this study, we analyzed the relationship between DNA
copy number and gene expression in tumor cells from
metastatic lymph nodes of 20 OSCC patients to: 1) iden-
tify the genes showing a significant correlation between
DNA copy number and gene expression, and 2) deter-
Figure 3 Correlation between DNA copy number and gene expression for genes in the high correlation region of chromosome 11q13.2-
q13.3. A. Locations of the genes and the unknown transcript in the region. B. DNA copy number (x-axis, base-2 log-transformed ratio of cancer to 
normal) and gene expression (y-axis, base-2 log-transformed intensity) of each gene in the 20 lymph node metastatic OSCC. For genes measured by 
multiple probe sets, the probe set with the strongest correlation is shown.Xu et al. Molecular Cancer 2010, 9:143
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mine which if any copy number-associated genes from
metastatic OSCC were associated with OSCC status and
survival. We used the same cells to isolate and amplify
DNA and RNA for high-throughput profiling whereas in
previous studies, DNA and RNA were interrogated either
from biopsy samples, or if tumor-cell specific, from two
different laser microdissected cell populations. To our
knowledge, this is the first time the genome and tran-
scriptome of a solid tumor have been profiled and inte-
grated using the genetic materials from the same cancer
cell population enriched by LCM. This is also the first
integrative analysis of DNA copy number and gene
expression of tumor cells from metastatic OSCC lymph
nodes.
There are a number of unresolved issues when inter-
preting data that integrate genome-wide DNA copy num-
ber and gene expression profiles. Study design, statistical
analyses and quality of specimens are all factors that can
all impact in how inferences are drawn between DNA
copy number and gene expression. An early study in
breast cancer indicated that at least 12% of all the vari-
ance in gene expression could be directly attributable to
the underlying variation in DNA copy number [11]. As
the authors pointed out, however, that was a significant
underestimate as DNA was obtained from tissue biopsies
with mixed tumor and stromal cells, reducing the ability
to detect tumor-associated CNA. In a more recent study
of non-small-cell lung carcinoma, 42% of the genes were
classified as DNA copy number-driven [23]. However, the
study did not enrich for tumor cells and dichotomized
genome CNA as loss and gain only, thereby limiting the
assessment of DNA copy number's impact on expression.
Another breast cancer study that enriched the tumor cells
via microdissection detected 46.7% of genes with a signif-
icant correlation between copy number and gene expres-
sion. However, that study did not appear to have adjusted
for multiple comparisons and this may lead to over-esti-
mation of the impact of copy number on gene expression
Table 1: Transcripts associated with survival
Gene Gene Title By Probe Set Note*
C7orf30 chromosome 7 open reading frame 30 226386_at OSCC associated
C8orf59 chromosome 8 open reading frame 59 1555241_at OSCC associated
C8orf76 chromosome 8 open reading frame 76 225702_at
CCT6A chaperonin containing TCP1, subunit 6A (zeta 1) 201327_s_at OSCC associated
DCAF13 DDB1 and CUL4 associated factor 13 225676_s_at OSCC associated
DNAJC8 DnaJ (Hsp40) homolog, subfamily C, member 8 212490_at OSCC associated
FADD Fas (TNFRSF6)-associated via death domain 202535_at OSCC associated
FAF2 Fas associated factor family member 2 212108_at OSCC associated
FUBP3 far upstream element (FUSE) binding protein 3 212824_at
MRPL15 mitochondrial ribosomal protein L15 218027_at OSCC associated
NFE2L2 nuclear factor (erythroid-derived 2)-like 2 201146_at OSCC associated
OSMR oncostatin M receptor 1554008_at OSCC associated
PPFIA1 protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 1
210235_s_at; 202066_at; 210236_at OSCC associated
PURB purine-rich element binding protein B 227718_at OSCC associated
RAD23B RAD23 homolog B (S. cerevisiae) 201223_s_at
RANBP6 RAN binding protein 6 213019_at
SSSCA1 Sjogren syndrome/scleroderma autoantigen 1 203114_at OSCC associated
STEAP3 STEAP family member 3 218424_s_at; 1554830_a_at OSCC associated
TOR1B torsin family 1, member B (torsin B) 209593_s_at OSCC associated
TREM1 triggering receptor expressed on myeloid cells 1 219434_at OSCC associated
UCK2 uridine-cytidine kinase 2 209825_s_at OSCC associated
VPS54 vacuolar protein sorting 54 homolog (S. cerevisiae) 222627_at OSCC associated
YIPF5 Yip1 domain family, member 5 224934_at
ZNF410 zinc finger protein 410 209944_at
*OSCC associated: gene is differentially expressed in OSCC vs. normal controls.Xu et al. Molecular Cancer 2010, 9:143
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[24]. Regardless of these limitations, data from these
studies and ours does point that, in general increased
DNA copy number was associated with increased expres-
sion. A critical issue is how to distinguish those copy
number-associated genes which are the true "drivers" of
carcinogenesis from those without functional relevance.
We believe that determining which copy number-associ-
ated transcripts are associated with clinical characteris-
tics and survival could be one approach to prioritize these
transcripts further.
One interesting finding is the complexity seen between
DNA copy number and gene expression for individual
CNA regions. In the same DNA region, it was not
unusual to find a mix of both genes the expression of
which did and did not show a correlation with CNA. For
instance, six genes and an unknown transcript located in
the high correlation 11q13.2-q13.3 region showed a
strong positive correlation between DNA copy number
and gene expression, whereas the expression of five other
genes located in the same region can not be explained by
their CNA. Previous studies have linked five of the six
copy number-associated genes in the 11q13.2-q13.3
region to cancer progression, including: 1) the genome
amplification and overexpression of ORAOV1  and
PPFIA1 associated with aggressive phenotypes in OSCC
cell lines [20,25]; 2) the expression of the cell apoptotic
signal mediator FADD associated with nodal metastasis
in non-small cell lung cancer [26] and poor survival in
laryngeal carcinoma [27]; and 3) the expression of CPT1A
and MRPL21 associated with the development of colon
cancer and breast cancer, respectively [28,29]. Therefore,
at least some associations between DNA copy number
and gene expression can be shown to have clinical or
pathogenetic relevance, as opposed to only representing a
DNA dosage effect.
M a n y  o f  t h e  g e n e  ca n d i da t e s  i d e n t i fi ed  i n  t h is  s t u d y
have mechanistic relevance in regards to how cancer cells
migrate from the primary organ to distant sites and sur-
vive through this process and in their new environment.
For example, out of the 116 OSCC specific genes, at least
20 are involved in either cell cycle or cell death. Similarly,
for the 24 genes associated with survival, 6 genes are
involved in cell death and 3 genes are involved in cell
migration. The expression changes of these genes, which
our study suggests occurs as a result of copy number
alterations, may enhance the viability and migration
capability of the cancer cells, thus assisting in the pro-
gression and spread of the OSCC. Further investigation
of these genes to confirm their roles in OSCC metastasis
is warranted.
Although genes with CNA-associated expression were
located on all chromosomal arms studied, several clusters
of such genes were observed (e.g., in the 11q13 region as
described above and other regions such as 7q22.1 and
9p24.1 (see Figure 2)). Likely, a single CNA event in these
regions would cause the dysregulated expression of mul-
tiple genes. It is generally believed that recurrent genome
CNA regions harbour genes that are essential to cancer
progression, but many current functional studies focus
on identifying the single "key driver gene" in the region of
CNA responsible for cancer progression. In a recent
study on liver cancer, however, the over-expression of
both cIAP1 and Yap, as a result of genome amplification
at mouse chromosome 9qA1, cooperatively promoted
tumorigenesis [16]. In another study of glioblastoma,
chromosome 12q13.3-14.1 amplification caused over-
expression of genes (CDK4  and  CENTG1) and a
microRNA (hsa-miR-26a), all of which were demon-
strated to contribute to the progression of the cancer [30].
Thus, CNA in these regions may be an efficient mecha-
nism for cancer cells to obtain functional benefits from
multiple genes (and even microRNAs) to achieve a spe-
cific aberrant capability. Likewise, amplification at 11q13
is one of the most frequently observed CNA events in
almost all solid tumors [31]. This single CNA event would
likely cause the over-expression of genes such as
Table 2: Hazard ratios association of AJCC stage and gene expression with survival
Model terms Hazard Ratio (95% CI*)
Unadjusted** 122-gene PC + stage 27-gene PC + stage
AJCC stage 2.24 (1.35-3.71) 2.13 (1.29-3.54) 2.04 (1.24-3.35)
122-gene 1st PC*** 1.22 (1.1-1.35) 1.2 (1.08-1.34)
122-gene 2nd PC 0.92 (0.83-1.03) 0.94 (0.84-1.04)
27-gene 1st PC 1.28 (1.14-1.44) 1.24 (1.11-1.39)
27-gene 2nd PC 1.34 (1.07-1.69) 1.27 (1.01-1.6)
* CI: Confidence Interval
**The unadjusted HRs refer to 3 separate models: one for AJCC stage, one for the two 122-gene PCs, and one for the two 27-gene PCs
***PC: Principal Component.Xu et al. Molecular Cancer 2010, 9:143
http://www.molecular-cancer.com/content/9/1/143
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ORAOV1,  PPFIA1, and FADD, which, as mentioned
above would synergize to promote OSCC progression.
For this reason, genes with copy number associated
expression in the regions of CNA reported in this study
should be considered in a comprehensive way as concur-
rent dysregulation of these genes could contribute to the
lymphotropic phenotype of these metastatic tumor cells.
The fact that among CNA-associated genes found in
tumor cells isolated from nodal metastases, we found
subsets that were significantly associated with OSCC sta-
tus and survival using expression profiles of biopsy sam-
ples from primary tumors which were not laser-dissected
suggests that the signal from our copy number-associated
genes was robust enough to overcome "noise" from the
expression signal of bystander cells. Moreover, the fact
that the two survival models incorporating the gene
expression of the '122- or 27-transcript PC' resulted in
higher AUCs than a model with stage alone suggests that
at least some of these copy number-associated transcripts
may have prognostic relevance and could aid in explain-
ing some of the outcome variation among tumors of the
same stage. Thus, although there may be some genes
irrelevant to the cancer process differentially expressed
due to a dosage effect of CNA, our data demonstrate that
integration of genome CNA with expression in tumor
cells with an aggressive phenotype (i.e. lymphotropism)
could uncover candidate biomarkers or therapeutic tar-
gets. However, larger scale integrative analysis with more
patient tissue samples is needed for further validation and
new discoveries of DNA copy number-associated genes.
In addition, functional studies are warranted to assess the
biological roles of these DNA copy number driven genes
in the OSCC progression.
Conclusions
In this study, we have presented 1) an approach to sys-
tematically integrate DNA copy number aberrations and
differential gene expression; 2) copy number-associated
genes associated with OSCC status and survival; and 3)
improved prognostication of 2-year survival using sur-
vival models based on copy number-associated tran-
scripts compared to those using the current clinical
standard, AJCC stage, alone. Further investigation is war-
ranted to confirm these findings and examine the biologic
role of these copy number-associated genes in OSCC
metastasis and their potential as therapeutic targets.
Methods
Tissue collection and specimen processing
As described previously in Chen et al [21], we identified
English-speaking patients 18 year of age or older with a
first, primary OSCC at any of three University of Wash-
ington-affiliated hospitals: University of Washington
Medical Center, Harborview Medical Center, and the
Puget Sound Veterans Affairs Health Care System. Meta-
static OSCC lymph nodes were snap-frozen at time of
surgical resection and stored in liquid nitrogen until use.
Tissue preparation, LCM of tumor cells, and extraction of
DNA and RNA from the same LCM-harvested cell popu-
lation was performed as previously described [32]. Puri-
fied RNA was stored in -80°C until use. Quantity and
quality of purified RNA and DNA from each specimen
was determined by ND-1000 spectrophotometer (Nano-
Drop Technologies, Wilmington, DE) and Agilent 2100
bioanalyzer (Agilent Technologies, Santa Clara, CA)..
Figure 4 ROC analysis of 2-year survival comparing AJCC stage 
with gene expression data. A, ROC curves for 2-year survival for mod-
els "stage," "122-PC," and "27-PC" B, ROC curves for 2-year survival for 
models "stage," "stage + 122-PC" and "stage + 27-PC".Xu et al. Molecular Cancer 2010, 9:143
http://www.molecular-cancer.com/content/9/1/143
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Purified DNA was dried on a Savant DNA Speed Vac 110
(Global Medical Instrumentation, Ramsey, MN), re-dis-
solved as 50 ng/μl in 10 mM Tris-HCl pH 8 with 0.1 mM
EDTA, and stored at -20°C until use [32].
Genome profiling with SNP array
The DNA was hybridized onto Affymetrix Human Map-
ping 250 K Nsp I SNP array (Affymetrix Inc., Santa Clara,
CA) following the manufacturer's instructions. Briefly,
250 ng of purified genomic DNA was digested with
restriction enzyme Nsp I, ligated to an Nsp I adaptor, and
PCR amplified. After purification, 90 μg of amplified
DNA were fragmented, biotin-labeled, and hybridized to
the SNP array. Intensity of the hybridized feature was
a c q u i r e d  w i t h  A f f y m e t r i x  G C O S  ( v 1 . 4 )  s o f t w a r e .  S N P
genotyping was performed with the Robust Linear Model
with Mahalanobis distance classifier algorithm (BRLMM)
in Affymetrix Genotyping Console (v3.0) software. Qual-
ity of the genome profiling process was assessed by the
yield and length range of the amplified DNA, the length
range of the fragmented DNA, and the SNP call rate fol-
lowing the manufacturer's instructions [32]. The SNP
array results were normalized through median smooth-
ing coupled with the Invariant Set Normalization method
in dChip [33]. We took the log2 ratio between our nor-
malized SNP array results and 2 which is the expected
number of DNA copies in a normal cell and estimated the
DNA copy number using the R package cghFlasso in ref-
erence to the Affymetrix 48 HapMap normal samples.
cghFlasso infers the underlying piecewise linear DNA
copy number profiles with fused lasso regression, and
calls gains and losses by controlling the overall false dis-
covery rate [34]. The location of each SNP probe set was
mapped to the human genome (Build 36.1) using Affyme-
trix annotation file 'Mapping250K_Nsp.na26.annot.csv'.
The genome DNA copy number of a transcript was calcu-
lated as: 1) the average genome DNA copy number
inferred from all the SNPs within the transcript if the
transcript overlapped with 5 or more SNPs; 2) the average
of the genome DNA copy numbers inferred by the closest
5 SNPs within a 250 kb neighboring region of the tran-
script; or 3) the average of the genome DNA copy num-
bers inferred by all the SNPs within 250 kb of the
transcript if there were fewer than 5 SNPs in this region.
Transcriptome profiling
The RNA was hybridized onto Affymetrix Human
Genome U133 Plus 2.0 array (Affymetrix Inc., Santa
Clara, CA) as previously described [7]. Briefly, 40 ng of
purified total RNA was amplified using Arcturus Ribo-
Amp Plus 1.5-round kit (Molecular Devices) following
the manufacturer's instructions. Amplified RNA was bio-
tin-labeled and fragmented using Affymetrix GeneChip
IVT Labeling kit and hybridized to the U133 Plus 2.0
array following manufacturer's protocol. Intensity of the
hybridized feature was acquired with Affymetrix GCOS
(v1.4) software. Quality of the transcriptome profiling
process was assessed by the yield and length range of the
amplified RNA, the length range of the fragmented RNA,
the average background, the "Present" call rate, and the
3'/5' ratio for glyceraldehyde-3-phosphate dehydrogenase
and ß-actin following the manufacturer's instructions
[32]. Gene expression profiles were normalized using the
R package gcRMA http://www.bioconductor.org.The
location of each transcript measured by each probe set
was mapped to the human genome (Build 36.1) using
Affymetrix annotation file 'HG-U133_Plus_2.na27'.
Transcript filtering
We eliminated transcripts which: 1) had no alignment
information (e.g., control probes) or no unique alignment
to the human genome; 2) were on the sex chromosome
and mitochondrial DNA; 3) had no expression values
greater than 3 on a log2 scale in at least 3 samples; and 4)
had an inter-quartile range of expression less than 0.1 on
a log2 scale [21].
Analysis of the association between DNA copy number and 
gene expression
T o ensure that the median of the expression data from
any sample or transcript was around zero with the same
variation across samples or transcripts, a second normal-
ization was employed after transcript filtering using the
following formula:
where ? is the median of Ys and |Y| is the absolute value
of Y. Our goal was to find genes with expression associ-
a t e d  w i t h  D N A  c o p y  n u m b e r .  F o r  t h i s  p u r p o s e ,  w e
e m pl oyed r o bus t  r egr es sio n t o  eva lua t e  t he  c orr e la t ion
between gene expression and DNA copy number across
OSCC samples. Compared to least square regression
(LSR), robust regression analysis provides an alternative
when fundamental assumptions are unfulfilled by the
nature of the data. In our case, it was equality of the error
variance along the predicted line that did not hold. We
used rlm function from R package MASS, in which itera-
tively reweighted least square algorithm was employed to
estimate parameters in the regression model. For each
gene, we fitted the model:
where Yi was the gene expression and Xi was the DNA
copy number estimated from the SNPs. Two-sided P-
value for the test of null hypothesis β = 0 was calculated
using the t-statistics from the robust regression with a
Y Yi Y median Yi Y i 1  2    n
∧
= () ( ) =… () –/ | – | , ,. , 
Yi Xi i is 1  2  number of transcripts =+ … () ab ,,,Xu et al. Molecular Cancer 2010, 9:143
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degree of freedom (df) = N-2 where N is the number of
samples.
Enrichment analysis of DNA copy number-associated 
transcripts
We identified copy number-associated transcripts meet-
ing a False Discovery Rate (FDR) of < 1% (n = 530 tran-
scripts) to determine if these represented an enriched
subset of transcripts associated with OSCC status or sur-
vival by using our previously published, independent
dataset comprising of 167 OSCC primary tumors and 45
normal controls [21], from which we excluded 19 patients
whose metastatic lymph nodes were used for generating
the CNA-associated transcripts. (1 OSCC patient whose
metastatic lymph nodes were used to identify CNA asso-
ciated transcripts was not part of Chen et al. 2008.). The
association between the expression of these transcripts
and being a case in this independent dataset comprising
of 148 OSCC cases and 45 controls was assessed using a
linear regression implemented by GenePlus software
[35,36]. To determine the association between expression
and survival, we analyzed expression array results for the
subset of the 148 OSCC patients for which we had at least
four months of follow-up time to reduce the inclusion of
deaths from patients due to co-morbidities rather than
tumor biology (n = 132). The association between expres-
sion and survival was estimated using Cox-regression
adjusting for age and sex. A dummy variable was created
for sex. Then to determine whether our copy number-
associated transcripts (n = 530) represented an enriched
subset of transcripts associated with OSCC (vs. normal
control), we compared the observed Z-score distribution
of the 530 transcripts to the expected Z-score distribu-
tion from randomly selecting a subset of transcripts the
same size one thousand times. This comparison of Z-
score distributions was repeated for survival.
Comparing survival prediction models with AJCC stage
Using the subset of copy number-associated transcripts
which were found to be associated with either the OSCC
status or survival in our enrichment analysis above, we
determined whether a model which incorporates gene
expression data predicts survival better than stage alone.
We first reduced the dimensionality of the gene expres-
sion data by calculating the first two principal compo-
nents summarizing the expression of a subset of copy
number-associated transcripts which in our enrichment
analysis were found to be either differentially expressed in
OSCC vs. normal control (n = 122) or associated with
survival (n = 27) using Matlab version R2006b. We
decided to include the transcripts associated with OSCC
(vs. normal control) in the survival prediction based on
our previously reported finding that a group of 131 genes
differentially expressed genes in OSCC identified OSCC
patients at high risk for poor survival [22]. W e fit five
summary Cox models of OSCC-specific survival. The
first model contained stage alone as a continuous predic-
tor, the second contained the first and second principal
components summarizing expression of the 122 tran-
scripts, and the third model contained first and second
principal components for the 27 transcripts. The fourth
and fifth models included principal components for the
122 and 27 transcripts respectively along with stage. Risk
scores were calculated using a jackknife leave-one-out
analysis for 4 models: two models using the first two prin-
cipal component scores from the two subsets of corre-
lated transcripts ('122 PC' and '27 PC'); and two other
models combining AJCC stage and the principal compo-
nent scores from either of the two transcript subsets
('stage + 122 PC' and 'stage + 27 PC'). For each model and
for AJCC stage, we then used an adapted Receiver Oper-
ating Characteristics (ROC) analysis [37] to construct
ROC curves for predicting two year survival as previously
described [22].
Ingenuity Pathways Analysis
The lists of the 122 and 27 transcripts were analyzed
using Ingenuity Pathway Analysis software (IPA, version
8.5, Ingenuity® Systems, http://www.ingenuity.com Core
Analysis. We used the default settings so the Functions/
Pathways/T ox list Analyses were performed with "Inge-
nuity Knowledge Base (Genes Only)" as reference set and
both direct and indirect relationships were considered in
the Network Analysis.
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